





A unit of Artemis Medicare Services Ltd.

#### November 15, 2024

The Secretary,
National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E),
Mumbai – 400 051

The Secretary, BSE Limited Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

NSE Code: ARTEMISMED Scrip Code: 542919

Sub: Earnings Presentation – Q2 and H1 FY25

Dear Sir/Ma'am,

With reference to the captioned subject, please find attached herewith the earnings presentation for the quarter/half year ended September 30, 2024.

The presentation is also available on the website of the Company i.e. www.artemishospitals.com.

Submitted for your information & records.

Thanking you.

Yours faithfully,

For Artemis Medicare Services Limited

Poonam Makkar Company Secretary & Compliance Officer

Encl: As above











**Care for Customer** 

**Respect for Associates** 

**Excellence through Teamwork** 

**Always Learning** 

**Trust Mutually** 

**Ethical Practices** 



(BSE: 542919; NSE: ARTEMISMED)

**Earnings Presentation Q2 and H1 FY2025** 

### Artemis Hospitals : At a Glance



Established in July 2007 by promoters of Apollo Tyres (67% ownership), Artemis Hospital is one of the leading healthcare service providers in Delhi NCR

842 beds across Artemis Hospital Gurgaon and other hospitals

Attractive platform for leading doctors given the strength of the brand

Business tie-up with over 100 corporates, both private and PSUs

Expanding footprint in Tier 1 & 2 cities through a chain of asset light centres

High quality of service supported by state of the art Equipment and Technology

One of the most preferred destination for international patients

Diverse business across multi-speciality, cardiac and maternity segments

Artemis Cardiac Care, a joint venture with Philips, operating cardiac care centres across India



500+ F

**Full time Doctors** 

40+

**Specialities** 


12


**Centres of Excellence** 


## Consolidated Financial Highlights – Q2 FY25



### **Key Financials**









**Dr. Devlina Chakravarty Managing Director** 

"We are pleased to announce the strong performance of Q2 FY25 and H1 FY25, with our continuous focus on all key metrics. We have been able to achieve our best-ever performance with the highest revenue and EBITDA margins, by harnessing economies of scale and improving cost efficiencies. We have also inaugurated the third tower, which will be operationalised in a phase-wise manner to cater to the increasing customer base and further enhance our operational and financial performance.

On the Operational front, we concentrated on refining the payer mix and removing bottlenecks, resulting in one of the industry-leading ARPOBs and improvement in margins. Our high revenue share from international patients underscores our role and recognition as a trusted centre for Medical Value Travel.

In line with our strategic growth initiatives, the Board has approved to enter into a long term Operations & Management and Medical Services Agreement in Raipur for a 300+ bed super speciality hospital subject to completion of customary closing conditions. This hospital will be operational in approx. one year and will help us extend our reach to central India. We are further exploring more expansion opportunities in the super-speciality segment, enabling us to leverage our brand, strengthen our presence and lay a foundation for future growth."

**EBITDA Includes Other Income** 

Margins calculated on Net Revenue from Operations


### Accreditations and Centres of Excellence



### **Accreditations**

### **Board for Hospitals & Healthcare Providers** National Accreditation Board National Accreditation Board for Hospitals & Healthcare for Hospitals & Healthcare **Providers Certified Nursing** Providers - Blood Bank / **Blood Centre** Services First hospital in Gurugram to receive accreditation by Joint Commission International (JCI), UKAS MANAGEMENT SYSTEMS **National Accreditation** Intertek ISO 27001 **Board for Hospitals &** Certificate Healthcare Providers -**Ethics Committee** The Laboratory services accredited by NABL based on ISO 15189:2012 for a specified scope of tests

### **Centres of Excellence**



# High End Quaternary Care Facilities







**Warm Ambience** 



**Pre and Post Op Care** 

### Strategic Growth Vision





Artemis Hospital,
Gurgaon



- We have opened the third tower, taking the capacity to 700+ beds, making it one of the largest hospitals in Delhi-NCR.
- The enhanced capacity will allow us to reap the benefits of economies of scale, further enhancing our operational efficiency. This tower shall be operationalised in a phase-wise manner.



Expansion in Super Speciality segment



Capacity enhancement by adding super speciality hospitals in the group in Delhi NCR / select Tier – 2 cities



Asset Light Model



Focus on strengthening the operations of the asset light hospital in a value accretive manner



Overseas
Operations and
Management



- Operating our first hospital with ~80 beds branded as 'Artemis Curepipe Hospital', which started in FY24
- Further plans in place to increase Artemis footprint in other international locations




- In view of the growing demand for affordable healthcare, expanding our bed capacity in existing and new hospitals
- Enhancing operational efficiency to cater growing demand
- Brand recognition and geographical advantage backed by the best-in-class technology and team of accomplished medical practitioners to reap the benefits of this growth





Artemis Hospital, Gurgaon

### **Artemis Hospital Overview**



Provides high end tertiary and quaternary care services across more than 40 specialities

First hospital in Gurgaon to get accredited by the Joint Commission International (JCI), in 2013


First Hospital in Haryana to get National Accreditation Board of Hospital (NABH) within 3 years of start up


First hospital in North India to have M6 Cyber Knife in 2017

12 Centres of Excellence at the hospital


| Period  | ARPOB      | Patient Volumes | Surgeries<br>Performed | Operational<br>Census Beds | Occupancy % | ALOS |  |
|---------|------------|-----------------|------------------------|----------------------------|-------------|------|--|
| Q2 FY25 | INR 78,800 | 99,803          | 3,498                  | 466                        | 69.4%       | 3.7  |  |
| H1 FY25 | INR 79,000 | 196,852         | 7,206                  | 461                        | 68.0%       | 3.7  |  |








#### **EBITDA and EBITDA Margin**



#### **Quarterly Performance Trend**



### **Key Highlights**

Reported 23.7% revenue
CAGR and 48.1% EBITDA
CAGR during FY22-24. The
strong growth in financial
metrics has been driven by:


- Leveraging economies of scale to improve operational efficiency through better allocation of fixed costs
- Plugging revenue leakages and running cost optimisation programs
- Supply chain and energy efficiency optimisations


#### Note:

EBITDA Includes Other Income


<sup>2.</sup> Margins calculated on Net Revenue from Operations















### Artemis' Ventures



#### **Overview**



affordable quality care

### Management Team





Onkar Kanwar Chairman

- A visionary entrepreneur, plays a pivotal role in the company's operations and articulation of its business philosophy
- Chairman of BRICS Business Council, India
- Served as the President of FICCI, Chairman of the automotive Tyre Manufacturers' Association in the past



Dr. Devlina Chakravarty
Managing Director

- Started her career in 1993 as a radiologist trained from Mumbai University. She did fellowships programmes from University of Berlin (Germany), UCLA (Los Angeles) and Brigham & Women (Boston)
- Before joining Artemis in 2007, worked as senior faculty & program director in radiology in different reputed hospitals in Delhi



Sanjiv Kumar Kothari Chief Financial Officer

- Qualified Chartered Accountant with 30 years of expertise in Finance & Accounts domain
- Spearheading the Finance team at Artemis since 2013
- Part of Apollo International as VP Accounts for 2+ years; prior to Apollo, worked for Ultratech cement & Gujrat Perstrop Electronics Ltd



Ashutosh Kumar Jha Chief – Strategy, M&A, Investor Relations and Organization Growth

- IIM and IIT alumnus with expertise in Strategy, M&A and Investments
- 18 years of experience across industries and private equity
- Previously Associated with Max Healthcare as Director and Head -Growth and M&A



Flt. Lt. Saras Malik Chief People Officer

- 23 years of managerial experience in Human Resources and Administration under the Indian Air Force and resultoriented measures of the Corporate
- Associated with Artemis for over 9 years. Prior to joining Artemis Hospital, she has worked with Fortis Healthcare for more than 5 years



Dr. Manju Aggarwal Chief Medical Services & Chairperson -Nephrology

- Worked as a Senior Consultant in Nephrology at Indraprastha Apollo Hospital, Delhi for 17 years
- Joined Artemis Hospitals as the Head of Nephrology and Kidney Transplantation in February 2012



Dr. Vishal Arora Chief of Business Transformation and Operational Excellence

- Holds an MBA healthcare from IIHMR Jaipur, senior leadership program from IIMA
- Extensive experience in Hospital
   Operations, Cost Optimization, Revenue
   Enhancement, Business Process
   Reengineering and has worked with all leading hospital across the country

### **Board of Directors**



#### Mr. Onkar Kanwar

#### Chairman and Non-Executive Director

- Former President of FICCI & ICC India, a former Director with the India's ECGC and KSIC, and former Chairman of ATMA
- Closely associated with leading national and international organizations

#### Mr. Neeraj Kanwar

#### Non-Executive Director

- An Engineering graduate from Lehigh University and has been associated with the company since 2008
- Currently holding the position of Vice Chairman and Managing Director of Apollo Tyres and also served as the Chairman of the Automotive Tyre Manufacturer's Association

## Ms. Deepa Gopalan Wadhwa Independent Director

- Served as Ambassador of India to Japan (2012-2015), Qatar (2009-2012) and Sweden (2005-2009)
- A graduate from Madras University, she has an undergraduate degree in Chemistry and a post graduate degree in English Literature

### **Dr. Nirmal Kumar Ganguly**

#### Non-Executive Director

- President of the Jawaharlal Institute of Post Graduate Medical Education and Research, Pondicherry and a former Director General of the Indian Council of Medical Research
- Associated with the Company since 2014

#### Mr. Sanjib Sen

#### **Independent Director**

- Senior Advocate at Supreme Court of India and has expertise in Constitutional Law, Corporate and taxation laws, Criminal and Civil laws
- Presently he is member of panel of Arbitrators of Indian Council of Arbitration at FICCI

### **Dr. Devlina Chakravarty**

#### **Managing Director**

- Completed her fellowships/ preceptorship programmes from University of Berlin, UCLA (LA) and Brigham & Women (Boston) in Head and Neck & Body Imaging
- Worked as senior faculty and Programme Director in Radiology in different reputed hospitals in Delhi before joining Artemis

#### Ms. Shalini Kanwar Chand

#### Non-Executive Director

- Founder and Chairperson of Pristine International Holdings
- Graduated from the University of Delhi and Post Graduation from Swinburne University of Technology, Australia

### Mangaldas & Co.

Mr. Akshay Chudasama

**Independent Director** 

Expertise in cross-border M&A and Private Equity

· Managing Partner of Shardul Amarchand

 Graduated from University of Bombay and LLB from London School of Economics, UK

#### **Mr. Sunil Tandon**

#### Independent Director

 Mechanical Engineer from Delhi College of Engineering and MBA with a gold medal from FMS, University of Delhi

#### Ms. Pallavi Shroff

#### **Independent Director**

- Managing Partner & National Practice Head, Dispute Resolution of Shardul Amarchand Mangaldas & Co.
- Graduated from University of Delhi, Master of Management Studies from JBIMS and LLB from Government Law College, Mumbai


## Q2 FY25 Operational Performance - Artemis Gurgaon





## H1 FY25 Operational Performance - Artemis Gurgaon








# **Financials**


# Historical Performance (Consolidated)




(INR Mn)

#### **Gross Revenue**






#### **EBITDA and EBITDA Margin**







#### Note:

L. EBITDA Includes Other Income

<sup>.</sup> Margins calculated on Net Revenue from Operations

# Q2 and H1 FY25 Financial Performance (Consolidated)



| Particulars (INR Mn)                   | Q2 FY25 | Q2 FY24 | YoY%         | Q1 FY25 | QoQ%  | H1 FY25 | H1 FY24      | YoY%   |
|--|---------|---------|--------------|---------|-------|---------|--------------|--------|
| Gross Revenue                          | 2,523   | 2,376   | 6.2%         | 2,344   | 7.6%  | 4,867   | 4,578        | 6.3%   |
| Net Revenue from Operations            | 2,414   | 2,250   | 7.3%         | 2,232   | 8.2%  | 4,646   | 4,345        | 6.9%   |
| Other Income                           | 74      | 24      | 207.2%       | 44      | 68.9% | 118     | 37           | 222.6% |
| Total Income                           | 2,489   | 2,274   | 9.4%         | 2,276   | 9.3%  | 4,765   | 4,382        | 8.7%   |
| Operative Expenses                     | 1,449   | 1,414   | 2.4%         | 1,340   | 8.2%  | 2,789   | 2,721        | 2.5%   |
| Employee Benefit Expenses              | 359     | 341     | 5.1%         | 359     | 0.0%  | 718     | 682          | 5.2%   |
| Other expenses                         | 184     | 152     | 20.8%        | 172     | 6.9%  | 356     | 322          | 10.6%  |
| EBITDA                                 | 497     | 366     | 35.8%        | 406     | 22.5% | 903     | 658          | 37.2%  |
| EBITDA Margin                          | 20.6%   | 16.3%   |              | 18.2%   |       | 19.4%   | <i>15.1%</i> |        |
| Depreciation and amortisation expenses | 112     | 100     | 12.2%        | 108     | 3.5%  | 220     | 191          | 14.9%  |
| EBIT                                   | 385     | 267     | 44.4%        | 298     | 29.4% | 683     | 467          | 46.4%  |
| EBIT Margin                            | 16.0%   | 11.9%   |              | 13.3%   |       | 14.7%   | 10.7%        |        |
| Finance Cost                           | 80      | 79      | 1.2%         | 81      | -1.9% | 161     | 148          | 9.2%   |
| PBT                                    | 306     | 188     | <i>62.6%</i> | 216     | 41.2% | 522     | 319          | 63.6%  |
| Total tax                              | 84      | 53      | 60.2%        | 51      | 64.7% | 135     | 86           | 57.1%  |
| PAT                                    | 221     | 135     | 63.5%        | 165     | 33.9% | 387     | 233          | 66.0%  |
| PAT Margin                             | 9.2%    | 6.0%    |              | 7.4%    |       | 8.3%    | 5.4%         |        |

Note:

L. EBITDA Includes Other Income

<sup>.</sup> Margins calculated on Net Revenue from Operations

## Q2 and H1 FY25 Financial Performance (Standalone)



| Particulars (INR Mn)                   | Q2 FY25 | Q2 FY24 | YoY%   | Q1 FY25 | QoQ%  | H1 FY25 | H1 FY24 | YoY%   |
|--|---------|---------|--------|---------|-------|---------|---------|--------|
| Gross Revenue                          | 2,454   | 2,290   | 7.2%   | 2,280   | 7.6%  | 4,733   | 4,406   | 7.4%   |
| Net Revenue from Operations            | 2,347   | 2,169   | 8.2%   | 2,169   | 8.2%  | 4,516   | 4,181   | 8.0%   |
| Other Income                           | 75      | 25      | 202.7% | 44      | 71.1% | 119     | 37      | 220.4% |
| Total Income                           | 2,422   | 2,194   | 10.4%  | 2,213   | 9.4%  | 4,634   | 4,218   | 9.9%   |
| Operative Expenses                     | 1,410   | 1,364   | 3.4%   | 1,303   | 8.2%  | 2,713   | 2,618   | 3.6%   |
| Employee Benefit Expenses              | 347     | 328     | 5.7%   | 347     | 0.2%  | 694     | 655     | 6.0%   |
| Other expenses                         | 172     | 144     | 19.6%  | 163     | 5.7%  | 334     | 302     | 10.5%  |
| EBITDA                                 | 493     | 358     | 37.7%  | 401     | 23.0% | 893     | 643     | 39.0%  |
| EBITDA Margin                          | 21.0%   | 16.5%   |        | 18.5%   |       | 19.8%   | 15.4%   |        |
| Depreciation and amortisation expenses | 106     | 94      | 13.1%  | 102     | 3.7%  | 208     | 180     | 15.8%  |
| EBIT                                   | 387     | 264     | 46.4%  | 298     | 29.6% | 685     | 463     | 48.0%  |
| EBIT Margin                            | 16.5%   | 12.2%   |        | 13.8%   |       | 15.2%   | 11.1%   |        |
| Finance Cost                           | 76      | 75      | 1.7%   | 77      | -1.3% | 153     | 140     | 9.7%   |
| PBT                                    | 311     | 189     | 64.1%  | 221     | 40.4% | 532     | 323     | 64.6%  |
| Total tax                              | 85      | 52      | 64.8%  | 52      | 63.3% | 137     | 86      | 59.4%  |
| PAT                                    | 226     | 138     | 63.9%  | 169     | 33.4% | 395     | 237     | 66.5%  |
| PAT Margin                             | 9.6%    | 6.3%    |        | 7.8%    |       | 8.7%    | 5.7%    |        |

EBITDA Includes Other Income

<sup>2.</sup> Margins calculated on Net Revenue from Operations

## **Balance Sheet Overview**



| Stand                                    | alone   |       | Consolidated                             |         |       |  |  |
|--|---------|-------|--|---------|-------|--|--|
| Particulars (INR Mn)                     | H1 FY25 | FY24  | Particulars (INR Mn)                     | H1 FY25 | FY24  |  |  |
| Total Shareholders Funds                 | 7,963   | 4,516 | Total Shareholders Funds                 | 7,986   | 4,547 |  |  |
| Total Loans                              | 2,422   | 2,382 | Total Loans                              | 2,558   | 2,535 |  |  |
| Other Long Term Liabilities / Provisions | 1,028   | 1,057 | Other Long Term Liabilities / Provisions | 1,014   | 1,045 |  |  |
| <b>Total Sources of Funds</b>            | 11,413  | 7,955 | <b>Total Sources of Funds</b>            | 11,558  | 8,127 |  |  |
| Net Fixed Assets                         | 7,620   | 7,327 | Net Fixed Assets                         | 7,785   | 7,527 |  |  |
| Other Non Current Assets                 | 563     | 513   | Other Non Current Assets                 | 448     | 387   |  |  |
| <b>Total Non Current Assets</b>          | 8,183   | 7,840 | <b>Total Non Current Assets</b>          | 8,233   | 7,914 |  |  |
| Net Current Assets                       | (476)   | (465) | Net Current Assets                       | (425)   | (400) |  |  |
| Cash and Bank Balances                   | 3,706   | 580   | Cash and Bank Balances                   | 3,750   | 613   |  |  |
| Total Application of Funds               | 11,413  | 7,955 | <b>Total Application of Funds</b>        | 11,558  | 8,127 |  |  |

### Disclosure



This presentation contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Artemis Medicare Services future business developments and economic performance.

While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Artemis Medicare Services Limited undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

### For further information, please contact:

Artemis Medicare Services Ltd.

Sanjiv K Kothari Simran Malhotra / Anvita Raghuram

Chief Financial Officer Churchgate Partners

+91 124 4511 111 +91 22 6169 5988

Sanjiv.kothari@artemishospitals.com Artemisteam@churchgatepartners.com